Membranous nephropathy in systemic lupus erythematosus: A therapeutic enigma

Nature Reviews Nephrology

Volumn 5, Issue 4, 2009, Pages 212-220

  Mok, Chi Chiu ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHLORAMBUCIL; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUDARABINE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PREDNISOLONE; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT;

AMENORRHEA; ARTERY THROMBOSIS; BLOOD PRESSURE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG TOLERABILITY; EXPERIMENTAL THERAPY; HEART PROTECTION; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MEMBRANOUS GLOMERULONEPHRITIS; MEMBRANOUS LUPUS NEPHROPATHY; MORBIDITY; MORTALITY; NAUSEA; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SIDE EFFECT; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; THROMBOSIS; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; VOMITING; ALGORITHM; DECISION TREE;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS; DECISION TREES; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS;

EID: 67049098014     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.14     Document Type: Review

References (68)

1. Mok, C. C. et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am. J. Med. 119, 355 e25-e33 (2006).
2. Vu, T. V. & Escalante, A. A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease. J. Rheumatol. 26, 2595-2601 (1999).
3. Mok, C. C., Tang, S. S. , To, C. H. & Petri, M. incidence and risk factors of thromboembolism in systemic lupus erythematosus: A comparison of three ethnic groups. Arthritis Rheum. 52, 2774-2782 (2005).
4. Bastian, H. M. et al. LUMiNA study Group. LUpus in Minority populations: NAture vs nurture. systemic lupus erythematosus in three ethnic groups. Xii. risk factors for lupus nephritis after diagnosis. Lupus 11, 152-160 (2002).
5. Wadee, S. , Tikly, M. & Hopley, M. Causes and predictors of death in south Africans with systemic lupus erythematosuS. Rheumatology (Oxford) 46, 1487-1491 (2007).
6. Mok, C. C. & Tang, S. S. incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosuS. Am. J. Med. 117, 791-795 (2004).
7. Gonzalez-Crespo, M. R., Lopez-Fernandez, J. i., Usera, G., Poveda, M. J. & Gomez-reino, J. J. Outcome of silent lupus nephritis. Semin. Arthritis Rheum. 26, 468-476 (1996).
8. Christopher-stine, L. et al. renal biopsy in lupus patients with low levels of proteinuria. J. Rheumatol. 34, 332-335 (2007).
9. Appel, G. B. et al. renal involvement in systemic lupus erythematosus (sLe): A study of 56 patients emphasizing histologic classification. Medicine (Baltimore) 57, 371-410 (1978).
10. Churg, J. & sobin, L. H. Renal Disease: Classification and Atlas of Glomerular Disease. (igaku-shoin, Tokyo, 1982).
11. Churg, J., Bernstein, J. & Glassock, R. J. Renal Disease: Classification and Atlas of Glomerular Diseases 2nd edn (igaku-shoin, New York, 1995).
12. Mok, C. C., wong, R. W. & Lau, C. S. Lupus nephritis in southern Chinese patients: clinicopathologic findings and long-term outcome. Am. J. Kidney DiS. 34, 315-323 (1999).
13. Huong, D. L. et al. renal involvement in systemic lupus erythematosuS. A study of 180 patients from a single center. Medicine (Baltimore) 78, 148-166 (1999).
14. Donadio, J. V. Jr, Hart, G. M., Bergstralh, E. J. & Holley, K. E. Prognostic determinants in lupus nephritis: A long-term clinicopathologic study. Lupus 4, 109-115 (1995).
15. Yang, L. Y., Chen, W. P. & Lin, C. Y. Lupus nephritis in children-a review of 167 patients. Pediatrics 94, 335-340 (1994).
16. Neumann, K. et al. Lupus in the 1980s: iii. influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin. Arthritis Rheum. 25, 47-55 (1995).
17. Adler, S. G., Johnson, K., Louie, J. S. , Liebling, M. R. & Cohen, A. H. Lupus membranous glomerulonephritis: different prognostic subgroups obscured by imprecise histologic classificationS. Mod. Pathol. 3, 186-191 (1990).
18. schwartz, M. M., Kawala, K., roberts, J. L., Humes, C. & Lewis, E. J. Clinical and pathological features of membranous glomerulonephritis of systemic lupus erythematosuS. Am. J. Nephrol. 4, 301-311 (1984).
19. Sloan, R. P., Schwartz, M. M., Korbet, S. M. & Borok, R. Z. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus nephritis Collaborative study Group. J. Am. Soc. Nephrol. 7, 299-305 (1996).
20. Weening, J. J. et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol. 15, 241-250 (2004).
21. Leaker, B., Fairley, K. F., Dowling, J. & Kincaid-smith, P. Lupus nephritis: clinical and pathological correlation. Q. J. Med. 62, 163-179 (1987).
22. Pasquali, S. et al. Lupus membranous nephropathy: long-term outcome. Clin. Nephrol. 39, 175-182 (1993).
23. Moroni, G., Maccario, M., Banfi, G., Quaglini, S. & Ponticelli, C. Treatment of membranous lupus nephritis. Am. J. Kidney DiS. 31, 681-686 (1998).
24. Chan, T. M. et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 8, 545-551 (1999).
25. Mercadal, L. et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol. Dial. Transplant. 17, 1771-1778 (2002).
26. Mok, C. C. et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: An open-label trial. Am. J. Kidney DiS. 43, 269-276 (2004).
27. Cramer, C. H. Jr et al. Clinical presentation and outcome in a cohort of paediatric patients with membranous lupus nephritis. Nephrol. Dial. Transplant. 22, 3495-3500 (2007).
28. sun, H. O. et al. Long-term outcome of Chinese patients with membranous lupus nephropathy. Lupus 17, 56-61 (2008).
29. Kasitanon, N., Petri, M., Haas, M., Magder, L. S. & Fine, D. M. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: A retrospective study of 29 cases. Lupus 17, 40-45 (2008).
30. Gruppo italiano per lo studio della Nefrite Lupica (GisNeL). Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Am. J. Kidney DiS. 19, 473-479 (1992).
31. Bono, L., Cameron, J. S. & Hicks, J. A. The very long-term prognosis and complications of lupus nephritis and its treatment. Q. J. Med. 92, 211-218 (1999).
32. Appel, G. B., Cohen, D. J., Pirani, C. L., Meltzer, J. I. & Estes, D. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the world Health Organization. Am. J. Med. 83, 877-885 (1987).
33. Dooley, M. A., Hogan, S. , Jennette, C. & Falk, R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int. 51, 1188-1195 (1997).
34. Mok, C. C. et al. risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis: A comparative study. Medicine (Baltimore) 86, 203-209 (2007).
35. Lai, K. N. Membranous nephropathy: when and how to treat. Kidney Int. 71, 841-843 (2007).
36. Asanuma, Y. et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosuS. N. Engl. J. Med. 349, 2407-2415 (2003).
37. schieppati, A., ruggenenti, P., Perna, A. & remuzzi, G. Nonimmunosuppressive therapy of membranous nephropathy. Semin. Nephrol. 23, 333-339 (2003).
38. Lee, T. M., Su, S. F. & Tsai, C. H. effect of pravastatin on proteinuria in patients with wellcontrolled hypertension. Hypertension 40, 67-73 (2002).
39. Donadio, J. V. Jr, Burgess, J. H. & Holley, K. E. Membranous lupus nephropathy: A clinicopathologic study. Medicine (Baltimore) 56, 527-536 (1977).
40. Gonzalez-Dettoni, H. & Tron, F. Membranous glomerulopathy in systemic lupus erythematosuS. Adv. Nephrol. 14, 347-364 (1985).
41. Mok, C. C., Lau, C. S. & Wong, R. W. S. risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 41, 831-837 (1998).
42. Wang, A. Y. et al. severe bone marrow failure associated with the use of alternating steroid with chlorambucil in lupus membranous nephropathy in Chinese. Lupus 10, 295-298 (2001).
43. Austin, H. A., Vaughan, E. M. & Balow, J. E. Lupus membranous nephropathy: randomized controlled trial of prednisone, cyclosporine and cyclophosphamide [Abstract]. J. Am. Soc. Nephrol. 11, 81A (2000).
44. radhakrishnan, J., Kunis, C. L., D'Agati, v. & Appel, G. B. Cyclosporine treatment of lupus membranous nephropathy. Clin. Nephrol. 42, 147-154 (1994).
45. Hallegua, D., Wallace, D. J., Metzger, A. L., Rinaldi, R. Z. & Klinenberg, J. R. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 9, 241-251 (2000).
46. Hu, W. et al. Cyclosporine A in treatment of membranous lupus nephropathy. Chin. Med. J. (Engl.) 116, 1827-1830 (2003).
47. Mok, C. C., Tong, K. H., To, C. H., Siu, Y. P. & Au, T. C. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study. Kidney Int. 68, 813-817 (2005).
48. Praga, M., Barrio, V., Juárez, G. F. & Luño, J. Grupo español de estudio de la Nefropatía Membranosa. Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int. 71, 924-930 (2007).
49. Maruyama, M. et al. Good response of membranous lupus nephritis to tacrolimuS. Clin. Nephrol. 65, 276-279 (2006).
50. Tse, K. C., Lam, M. F., Tang, S. C., Tang, C. S. & Chan, T. M. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus 16, 46-51 (2007).
51. Ginzler, E. M. et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353, 2219-2228 (2005).
52. Contreras, G. et al. sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350, 971-980 (2004).
53. Kapitsinou, P. P., Boletis, J. N., skopouli, F. N., Boki, K. A. & Moutsopoulos, H. M. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford) 43, 377-380 (2004).
54. spetie, D. N. et al. Mycophenolate therapy of sLe membranous nephropathy. Kidney Int. 66, 2411-2415 (2004).
55. Karim, M. Y. et al. reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 44, 1317-1321 (2005).
56. Mok, C. C. & Lai, K. N. Mycophenolate mofetil in lupus glomerulonephritis. Am. J. Kidney DiS. 40, 447-457 (2002).
57. Mok, C. C. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: A systematic revieW. Scand. J. Rheumatol. 36, 329-337 (2007).
58. Sinclair, A. et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management study (ALMs). Lupus 16, 972-980 (2007).
59. Houssiau, F. A. & Ginzler, E. M. Current treatment of lupus nephritis. Lupus 17, 426-430 (2008).
60. Mok, C. C. et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. 50, 2559-2568 (2004).
61. Moroni, G. et al. withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol. Dial. Transplant. 21, 1541-1548 (2006).
62. Lui, S. L. et al. rapamycin attenuates the severity of established nephritis in lupus-prone NZB/w F1 mice. Nephrol. Dial. Transplant. 23, 2768-2776 (2008).
63. ramos-Barrón, A. et al. Prevention of murine lupus disease in (NZB x NZw)F1 mice by sirolimus treatment. Lupus 16, 775-781 (2007).
64. Medina, F., Fuentes, J., Carranza, i., Fraga, A. & Moreno, J. sirolimus: A potential treatment for diffuse proliferative lupus nephritis [Abstract]. Ann. Rheum. DiS. 65 (Suppl. 2), s351 (2006).
65. Leandro, M. J., Cambridge, G., edwards, J. C., ehrenstein, M. R. & isenberg, D. A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients. Rheumatology (Oxford) 44, 1542-1545 (2005).
66. Gunnarsson, i. et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56, 1263-1272 (2007).
67. Boumpas, D. T. et al. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin. Nephrol. 52, 67-75 (1999).
68. Aringer, M., Graninger, W. B., Steiner, G. & Smolen, J. S. safety and efficacy of tumor necrosis factor á-blockade in systemic lupus erythematosus: An open- label study. Arthritis Rheum. 50, 3161-3169 (2004).